IMGN529 FDA Approval Status
FDA Approved: No
Brand name: IMGN529
Company: ImmunoGen, Inc.
Treatment for: Non-Hodgkin's Lymphoma
IMGN529 is a CD37-targeting Antibody-Drug Conjugate (ADC) in development for the treatment of non-Hodgkin's Lymphoma and other B-cell malignancies.
Development timeline for IMGN529
|Sep 23, 2011||ImmunoGen, Inc. Announces Submission of IND for Wholly Owned Product Candidate for Non-Hodgkin's Lymphoma|
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.